---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-213225"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:26:58.817553+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics appoints Dr. Jakob Dupont to Board; two directors resign

## Summary
- James Healy, M.D., Ph.D., resigned from Board effective Sept 3, 2024; no disagreement with company.
- Frank D. Lee also resigned from Board effective Sept 3, 2024; no disagreement with company.
- Board appointed Jakob Dupont, M.D., Ph.D., as Class II director effective Sept 3, 2024.
- Dr. Dupont is Executive Venture Partner at Sofinnova Investments; former Global Head of R&D at Atara Bio.

## SEC filing metadata
- accession: 0001193125-24-213225
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/0001193125-24-213225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/d886159d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-213225
- JSON: https://secwatch.observer/filing/0001193125-24-213225.json
- Plain text: https://secwatch.observer/filing/0001193125-24-213225.txt

## Key facts
- Executive change
  Jakob Dupont was appointed as Class II member of the Board at Bolt Biotherapeutics, Inc..
  - Action: appointed
  - Role: Class II member of the Board
  source text: Effective September 3, 2024, the Board appointed Jakob Dupont, M.D., Ph.D., to serve as a Class II member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/0001193125-24-213225-index.htm
- Executive change
  Frank D. Lee resigned as member of the Board at Bolt Biotherapeutics, Inc..
  - Action: resigned
  - Role: member of the Board
  source text: On September 1, 2024, Frank D. Lee notified the Company of his resignation as a member of the Board and the committees thereof, effective as of September 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/0001193125-24-213225-index.htm
- Executive change
  James Healy resigned as member of the Board at Bolt Biotherapeutics, Inc..
  - Action: resigned
  - Role: member of the Board
  source text: On August 28, 2024, James Healy, M.D., Ph.D., notified Bolt Biotherapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and the committees thereof, effective as of September 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/0001193125-24-213225-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.